Targeted by checkpoint blockade immunotherapies to trigger antitumor immunity, the expression of PD-L1 in immune cells within the TME, rather than on tumor cells, is critical for the effectiveness of these therapies [130,131]. Here, CD274 is linked to neoplasm.